司美格鲁肽联合头孢哌酮钠舒巴坦治疗2型糖尿病并发肺炎的临床分析

目的分析司美格鲁肽注射液联合头孢哌酮钠舒巴坦对2型糖尿病并发肺炎患者治疗效果及肺功能的影响。 方法选择在2021年10月至2022年9月我院收治的2型糖尿病并发肺炎患者67例，随机分为观察组36例，对照组31例，对照组采用传统降糖联合头孢哌酮钠舒巴坦，观察组在对照组基础上采用司美格鲁肽注射液。比较两组治疗前后血糖空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)]、肺功能第一秒用力呼气容积(FEV₁)、用力肺活量(FVC)、最大呼气流量(PEF)FEV₁/FVC]、炎症因子白细胞介素-1(IL-1)、降钙素原(PCT)、C反应蛋白(CRP)]、临床疗效及不良反应。 结果治疗后FPG(5.41±0.78) mmol/L vs.(6.61±0.89) mmol/L、2hPG(7.22±1.15)vs. (8.86±1.25) mmol/L、HbA1c(4.56±0.71)% vs. (5.42±0.84)%、IL-11(0.21±1.86 )pg/L vs. (17.52±2.54) pg/L、PCT(0.18±0.02) ng/ml vs. ( 0.41±0.06) ng/ml、CRP(8.24±1.13) mg/L vs. ( 15.24±1.62) mg/L，观察组低于对照组(P<0.05)，治疗后FEV₁(2.58±0.35)L vs. (2.11±0.28)L、FVC(3.66±0.42)L vs. (3.18±0.46)L、PEF(36.65±4.56)L/s vs. (30.01±4.41)L/s、FEV₁/FVC(71.24±6.51)% vs. (65.25±6.23)%，观察组高于对照组(P<0.05)；治疗总有效观察组29例(93.55%)高于对照组26例(72.22%)(P<0.05)；两组不良反应差异无统计学意义。 结论司美格鲁肽注射液联合头孢哌酮钠舒巴坦治疗2型糖尿病并发肺炎效果好，可控制血糖，改善肺功能，降低炎症因子水平具有临床意义。

Clinical analysis of Smeglutide combined with Cefoperazone Sodium Sulbactam in patients with type 2 diabetes and pneumonia

ObjectiveTo analyze the effects of Smeglutide injection combined with Cefoperazone Sodium Sulbactam on the therapeutic effect and lung function of patients with type 2 diabetes complicated with pneumonia. MethodsAll of 67 patients with type 2 diabetes complicated with pneumonia admitted to our hospital from October 2021 to September 2022 were randomly divided into observation group (36 cases) and control group (31 cases). The control group received traditional hypoglycemic therapy combined with Cefoperazone Sodium Sulbactam, and the observation group received Smeclutide injection on the basis of the control group. Blood glucose fasting blood glucose (FPG), 2 h postprandial blood glucose (2hPG), glycohemoglobin (HbA1c)], lung functionforced expiratory volume in the first second (FEV₁), forced vital capacity (FVC), maximum expiratory flow (PEF) FEV₁/FVC], inflammatory factors interleukin-1 (IL-1), Procalcitonin (PCT), C-reactive protein (CRP)], clinical efficacy and adverse reactions. ResultsFPG (5.41±0.78)mmol/L vs. (6.61±0.89)mmol/L, 2hPG (7.22±1.15) vs. (8.86±1.25)mmol/L, HbA1c (4.56±0.71) % vs. (5.42±0.84)%, IL-11 (0.21±1.86)pg/L vs. (17.52±2.54)pg/L, PCT (0.18±0.02)ng/ml vs. (0.41±0.06)ng/ml, CRP (8.24±1.13)mg/L vs. (15.24±1.62)mg/L observation group was lower than control group (P<0.05). After treatment, FEV₁(2.58±0.35)L vs. (2.11±0.28)L, FVC(3.66±0.42)L vs. (3.18±0.46)L, PEF(36.65±4.56)L/s vs. (30.01±4.41)L/s, FEV₁/FVC(71.24±6.51)% vs. (65.25±6.23)% in observation group were higher than those in control group (P<0.05); 29 cases (93.55%) in the observation group were higher than 26 cases (72.22%) in the control group (P<0.05). There was no significant difference in adverse reactions between the two groups. ConclusionSmeiglutide injection combined with Cefoperazone Sodium Sulbactam is effective in the treatment of type 2 diabetes mellitus complicated with pneumonia, which can control blood sugar, improve lung function, reduce the level of inflammatory factors and reduce the incidence of adverse reactions.